Literature DB >> 29692820

Magnetic resonance imaging findings in diagnosis and prognosis of Wilson disease.

Mehri Salari1, Emad Fayyazi1,2, Omid Mirmosayyeb1,2.   

Abstract

Wilson disease (WD) is a rare autosomal recessive disorder characterized by excessive copper deposition in the body, principally in the liver and the brain. There is a wide spectrum of clinical presentations, but the most significant and basic symptoms of the disease can be divided into hepatic, neurologic, and psychiatric manifestations. Magnetic resonance imaging (MRI) provides more detailed anatomical information than computed tomography of the brain, especially of the structure of the basal ganglia and brain stem. In this review, we want to evaluate the correlation between MRI findings and clinical features of WD.

Entities:  

Keywords:  Hepatocerebral degeneration; Wilson disease; magnetic resonance imaging

Year:  2018        PMID: 29692820      PMCID: PMC5894273          DOI: 10.4103/jrms.JRMS_362_16

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


INTRODUCTION

Wilson disease (WD) is a rare autosomal recessive disorder characterized by excessive copper deposition in the body, principally in the liver and the brain. The involved gene ATP7B encodes a copper-transporting P-type ATPase. More than 500 ATP7B mutations have recently been identified. Less common genetic pathways, including complete exon deletions, promoter region mutations, simultaneous presence of three pathogenic variations, and monogenic disomy have also been detected but are relatively rare. Loss of ATP7B function results in reduced hepatic biliary copper excretion reduced assimilation of copper into ceruloplasmin and the accumulation of copper in many tissues.[1] There is a wide spectrum of clinical presentations, but the most significant and basic symptoms of the disease can be divided into hepatic, neurologic, and psychiatric manifestations. The neurologic presentation develops in almost 40%–50% of patients and typically begins in the second or third decade. Tremor is the most common neurologic symptom occurred in about 80% patients with the neurologic manifestation. The diagnosis of WD is based on the detection of Kayser–Fleischer rings, low ceruloplasmin, raised urine and hepatic copper level, signs of liver and/or neurologic deficit, and related histologic alterations in the liver.[2] Magnetic resonance imaging (MRI) is the most important neuroradiological instrument for the monitoring of both diagnosis and treatment in WD. The typical MRI finding is designated as symmetric hyperintensity or mixed intensity in T2-weighted (T2W) images in the pons, midbrain, and basal ganglion. The cerebellum, corticospinal tracts, cortex, and subcortical area are also affected. Theoretically, pathognomonic MRI findings include “the faces of the giant and miniature panda” and the “trident” signs was also reported in other neurodegenerative disorders.[3] In this review, we want to evaluate the correlation between MRI findings and clinical features of WD.

METHODS

Two of authors (OM and EF) independently searched the Medline, Central Register of Controlled Trials, and clinicaltrials.gov databases (published between January 01, 2000, and July 31, 2016) using the terms WD, MRI, and hepatolenticular degeneration. A comprehensive literature search was performed by an author with expertise in neurology and systematic review methodology. Review articles and references of all papers were assessed for potentially related studies.

Inclusion criteria

The following criteria were used to include studies: WD was defined according to accepted international diagnostic criteria MRI findings in WD were calculated Papers were published in English. After removing duplicate data, abstracts, and in some cases, full text of paper, were screened by two reviewers independently to assess the eligibility of the study to be included in our study. All potentially eligible studies were reviewed independently by the two trained reviewers (OM and EF). Any discrepancies following full article review were solved by a third reviewer (MS).

MAGNETIC RESONANCE IMAGING FINDINGS OF WILSON DISEASE

WD is an inherited autosomal recessive disease of copper metabolism resulting in copper toxicity. This wasfirst described in 1912 by Kinnier Wilson as “progressive lenticular degeneration.”[4] Inborn defect in copper metabolism characterized by abnormal accumulation of copper in several tissues, particularly in the liver and the brain. MRI findings were used in the clinical treatment of patients with WD.[5] Brain MRI in WD patients takes a main place for the diagnosis of these neurological forms. Structural brain MRI demonstrates extensive atrophy, and hypersignals in fluid-attenuated inversion recovery (FLAIR) and diffusion sequences in basal ganglia, cerebellar peduncles, and midbrain.[6] Hyposignals in FLAIR sequences can be seen at a later stage of the disease after several years of treatment. In hepatic forms with portacaval shunt, nonspecific bilateral striatal hypersignals are observed on T1 sequences.[7] Abnormalities of corticosubcortical white matter, compared with the deep nuclear structures, have received less consideration in WD. White-matter changes are observed in about 25%–40% of patients, often asymmetrical with frontal preference.[8] MRI revealed abnormalities in the basal ganglia, cerebral white matter, midbrain, pons, and cerebellum. The paramagnetic effects of copper were found only in untreated patients. Patients with a longer duration of WD had less severe changes in signal intensity. The most commonly affected site seen on MRI was the putamen, with a distinctive lateral rim of high-signal intensity on the T2W images. Abnormalities in the remainder of the basal ganglia, namely, the ventral nuclear mass of the thalami, caudate, and globus pallidus, were found only in the presence of an abnormal putamen. The second most commonly affected site was the pons, followed by the midbrain, cortical white matter, and cerebellum. Abnormalities in signal intensity were most commonly seen on the T2W images.[6] MRI provides more detailed anatomical information than CT of the brain, especially of the structure of the basal ganglia and brain stem. It also provides biochemical information on the distribution of heavy metal in the brain substance; MRI is clearly a useful method for assessing heavy metal storage disease.[9] Hence, there are known signs of WD on MRI. On T2W images, the signal intensities of the basal ganglia may change. An increased signal is considered as a correlate of toxic damage and can be partly reversible.[10] In the study of Alanen et al., MRI of the patients showed high-signal intensity areas in posterior thalamus, general atrophy, and pontine myelinolysis were present in the patients with clinical manifestations. The T2 measurement of these areas confirmed the result of image analysis. Apart from general atrophy, the changes in the patients with clinical disease were largely reversible.[11] Published MRI studies of WD have shown a number of abnormalities, including focal atrophy, high-intensity lesions, as well as hypodense areas on T2W imaging. Attempts have formerly been made to correlate these MRI changes with clinical progression or diagnosis, with varying degrees of success. Other imaging modalities have also been used in conjunction with MRI, including positron emission tomography and single-photon emission computed tomography.[12] Further, abnormalities may occur in the brainstem (e.g., the face of the giant panda's sign).[13] The T2W horizontal section of the midbrain in these patients showed the “face of giant panda” appearance, which we describe for thefirst time and is specific for WD. Hyperintensity in the T2W image was also observed in the pontine tegmentum, medulla oblongata, and the cerebellar white matter around the dentate nucleus; the latter structures were thought to be normal. The superior colliculus, which in normal controls show the same signal intensity as cerebral white matter, showed a remarkable decrease in signal intensity in the patients with WD.[9] In some WD patients treated with D-penicillamine with reduced dietary copper, T2W MRI showed high-intense integrities symmetrically in the bilateral lenticular nuclei and thalami in the right frontal subcortical white matter. In one study found that the basal ganglia was the most frequently affected site and always involved the putamen, with abnormality in the globus pallidus, caudate, and thalami occurring in about half of the WD patients.[6] Hence, the MRI findings in WD patients represent the neuropathologic spectrum of spongy to cystic degeneration of gray matter nuclei; central pontine myelinolysis; and softening, gliosis, and demyelination of nerve fibers [Table 1].
Table 1

Clinical studies on the correlation of magnetic resonance imaging findings in Wilson disease

Clinical studies on the correlation of magnetic resonance imaging findings in Wilson disease

CORRELATION OF MAGNETIC RESONANCE IMAGING FINDINGS WITH CLINICAL CHARACTERISTICS OF WILSON DISEASE

There are the ranges of abnormalities seen on cranial MRI of patients with WD, and they correlate the findings with clinical severity, duration of disease, and duration of neurologic signs and symptoms before treatment.[6] Regarding to dysarthria, most consistent pathological feature was globus pallidus and then thalamus, also about tremor. Chorea mostly accompanying with caudate lesions, nystagmus with lentiform lesions and thalamus, rigidity with lentiform, white matter and thalamus lesions, and dystonia with globos pallidus and putamen. In one study about a few patients with WD, T2W MRI of the midbrain in all three revealed the characteristic “face of the giant panda” sign, consisting of high signal intensity in the tegmentum except for red nucleus, preservation of signal intensity of the lateral portion of the pars reticulata of the substantia nigra, and hypointensity of the superior colliculus. There clinical manifestations in these patients with these MRI pattern were rigidity, dysarthria, and also showed tremor and dystonia.[9] In another study brain, MRI revealed symmetrical hyperintensities on T2/T2 fluid attenuation inversion recovery images in the putamen, thalami, midbrain, pons, and subcortical white matter of both frontal lobes in one patient with decreased sleep, irrelevant speech, aggressive, and bizarre behavior.[14] The severity of changes in signal intensity on MRI was inversely related to the duration of untreated disease and similarly related to the overall duration of disease. In contrast, no significant relationship was found between the extent of disease seen on MRI and the total duration of disease or its untreated duration. Neurologic severity was unrelated to the duration of untreated disease or to total duration of disease.[6]

CONCLUSION

MRI is the most important neuroradiological instrument for the monitoring of both diagnosis and treatment in WD. MRI studies of WD have demonstrated a number of abnormalities, including focal atrophy and high-intensity lesions, as well as hypodense areas on T2W imaging. Attempts have formerly been made to correlate these MRI changes with clinical progression or diagnosis, with varying degrees of success. More clinical studies should be done to clarify the role of MRI findings in the diagnosis and prognosis of WD.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  14 in total

1.  "Split thalamus": internal medullary involvement in Wilson's disease.

Authors:  Uttam George; Nunenga Varte; Shubhra Rathore; Vishesh Jain; Sandeep Goyal
Journal:  Neurol India       Date:  2010 Jul-Aug       Impact factor: 2.117

2.  A study of MRI changes in Wilson disease and its correlation with clinical features and outcome.

Authors:  A Ranjan; J Kalita; S Kumar; S K Bhoi; U K Misra
Journal:  Clin Neurol Neurosurg       Date:  2015-07-21       Impact factor: 1.876

3.  Wilson's disease: cranial MRI observations and clinical correlation.

Authors:  S Sinha; A B Taly; S Ravishankar; L K Prashanth; K S Venugopal; G R Arunodaya; M K Vasudev; H S Swamy
Journal:  Neuroradiology       Date:  2006-06-03       Impact factor: 2.804

4.  The Clinical Utility of a Low Serum Ceruloplasmin Measurement in the Diagnosis of Wilson Disease.

Authors:  D Kelly; G Crotty; J O'Mullane; M Stapleton; B Sweeney; S S O'Sullivan
Journal:  Ir Med J       Date:  2016-01

5.  Cranial MR imaging in Wilson's disease.

Authors:  A D King; J M Walshe; B E Kendall; R J Chinn; M N Paley; I D Wilkinson; S Halligan; M A Hall-Craggs
Journal:  AJR Am J Roentgenol       Date:  1996-12       Impact factor: 3.959

6.  Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London) Brain 1912: 34; 295-509.

Authors:  Alastair Compston
Journal:  Brain       Date:  2009-08       Impact factor: 13.501

7.  ATP7B Gene Mutations in Croatian Patients with Wilson Disease.

Authors:  Hana Ljubić; Mirjana Kalauz; Srđana Telarović; Peter Ferenci; Rajko Ostojić; Maria Cristina Noli; Maria Barbara Lepori; Irena Hrstić; Jurica Vuković; Marina Premužić; Davor Radić; Katja Grubelić Ravić; Jadranka Sertić; Ana Merkler; Ana Acman Barišić; Georgios Loudianos; Boris Vucelić
Journal:  Genet Test Mol Biomarkers       Date:  2016-01-22

8.  Sequential MRI changes in Wilson's disease with de-coppering therapy: a study of 50 patients.

Authors:  S Sinha; A B Taly; L K Prashanth; S Ravishankar; G R Arunodaya; M K Vasudev
Journal:  Br J Radiol       Date:  2007-08-20       Impact factor: 3.039

9.  Seven-tesla magnetic resonance imaging in Wilson disease using quantitative susceptibility mapping for measurement of copper accumulation.

Authors:  Dominik Fritzsch; Martin Reiss-Zimmermann; Robert Trampel; Robert Turner; Karl-Titus Hoffmann; Andreas Schäfer
Journal:  Invest Radiol       Date:  2014-05       Impact factor: 6.016

10.  Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease.

Authors:  R A Page; C A Davie; D MacManus; K A Miszkiel; J M Walshe; D H Miller; A J Lees; A H V Schapira
Journal:  Neurology       Date:  2004-08-24       Impact factor: 9.910

View more
  2 in total

1.  Olfactory function and olfactory bulb volume in Wilson's disease.

Authors:  Nazan Degirmenci; Bayram Veyseller; Hasmet Hanagasi; Basar Bilgic; Defne Gurbuz; Ali Toprak; Orhan Ozturan
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-11-22       Impact factor: 2.503

2.  Can Disruption of Basal Ganglia-Thalamocortical Circuit in Wilson Disease Be Associated with Juvenile Myoclonic Epilepsy Phenotype?

Authors:  Jessica Rossi; Francesco Cavallieri; Giada Giovannini; Francesca Benuzzi; Daniela Ballotta; Anna Elisabetta Vaudano; Francesca Ferrara; Sara Contardi; Antonello Pietrangelo; Elena Corradini; Fausta Lui; Stefano Meletti
Journal:  Brain Sci       Date:  2022-04-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.